Influences that affect liver transplantation outcomes comprise numerous hepatic and extrahepatic factors, including hepatitis C infection. Patients with HCV are at risk for progression to liver damage and cirrhosis, which can affect the rate of waitlist mortality. In recent years, the introduction of direct-acting antivirals and improved management of cirrhosis have led to better outcomes post-liver transplant.
The following recent reports cover liver transplantation outcomes and waitlist predictive factors related to HCV infection, including cases in which patients also had diabetes, and comorbidities such as hepatitis B, as well as the safety and efficacy of preemptive DAA therapy.
- DAA therapy improves HCV-related liver transplantation outcomes
- HCV liver cancer resection outcomes similar in patients with diabetes
- NASH, HCV cirrhosis predict coronary artery disease in liver transplantation
- Alcoholic liver disease overtakes HCV as leading indication on liver waitlist
- Liver waitlist outcomes for patients with HCV improving in recent years
- NAT testing is a better indicator of hepatitis C positivity or negativity in donors (AF- I added this title since title was missing from report)
- Preemptive DAA therapy viable for HCV-positive liver transplantation
- HBV, HCV diagnoses show improved timing in late-stage liver disease